Magnitude Biosciences
Latest round
- —
Last raised
- Sep 2026
Total raised
- $2.3M
Investors
- 6
About Magnitude Biosciences
Based in Sedgefield, UK and Founded in 2018, and co-founded by David Weinkove, Chris Saunter. and Fozia Saleem serves as the CEO of the company. Magnitude Biosciences Ltd. specializes in drug development and research processes, leveraging C. elegans-based assays. Magnitude Biosciences specializes in advanced C. elegans-based assays designed to enhance drug development and research across various sectors, including biotechnology, pharmaceuticals, and academia. Their core offerings include high-throughput screening for age-related compounds, toxicity assessments, and microbiome studies, all conducted using their proprietary WormGazer™ technology. The assays provide valuable insights into the effects of compounds on neurodegeneration, chronic toxicity, and ageing, enabling clients to obtain reproducible data crucial for decision-making. The company's services are tailored to meet the needs of diverse clients, including health and nutrition firms, biotech companies, and academic institutions, focusing on delivering results efficiently within three weeks. Magnitude Biosciences operates in key markets including North America, Europe, and parts of Asia, providing tailored support to clients seeking innovative solutions in their research and development efforts. Magnitude Biosciences generates revenue through contract lab services structured primarily as B2B transactions with clients in the biotechnology, pharmaceutical, and academic sectors. Clients engage the company to conduct customized C. elegans studies, leveraging its expertise to gather high-quality, reproducible data on various research questions. The revenue model is based on project-based fees associated with specific assays, including flagship offerings related to microbiome research and neurodegenerative disease studies. Transaction structures may include upfront payments for specific projects or milestone-based payments as data is generated and delivered. By leveraging their unique technology and specialized expertise, Magnitude Biosciences fosters long-term partnerships with clients, ensuring a steady revenue stream through ongoing research projects.
Who invested in Magnitude Biosciences
6 investors across 3 rounds
See all investors in Magnitude Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Magnitude Biosciences
Who invested in Magnitude Biosciences?
Magnitude Biosciences has 6 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Magnitude Biosciences raised?
Magnitude Biosciences has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
What does Magnitude Biosciences do?
Based in Sedgefield, UK and Founded in 2018, and co-founded by David Weinkove, Chris Saunter.
Where is Magnitude Biosciences headquartered?
Magnitude Biosciences is headquartered in UK.
Which VCs invest in companies like Magnitude Biosciences?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Magnitude Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups
Raising like Magnitude Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.